Bank of New York Mellon Corp trimmed its holdings in shares of IRIDEX Corporation (NASDAQ:IRIX) by 38.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,048 shares of the medical equipment provider’s stock after selling 8,771 shares during the period. Bank of New York Mellon Corp owned 0.12% of IRIDEX Corporation worth $139,000 as of its most recent SEC filing.

Separately, LMR Partners LLP acquired a new stake in IRIDEX Corporation during the 2nd quarter valued at $242,000. 48.24% of the stock is owned by hedge funds and other institutional investors.

Shares of IRIDEX Corporation (NASDAQ IRIX) opened at $8.84 on Tuesday. IRIDEX Corporation has a 52 week low of $7.58 and a 52 week high of $16.39.

COPYRIGHT VIOLATION WARNING: “IRIDEX Corporation (IRIX) Position Trimmed by Bank of New York Mellon Corp” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/07/iridex-corporation-irix-position-trimmed-by-bank-of-new-york-mellon-corp.html.

IRIX has been the subject of several research reports. Roth Capital reissued a “buy” rating and issued a $13.00 target price on shares of IRIDEX Corporation in a research note on Friday. Zacks Investment Research raised IRIDEX Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th.

IRIDEX Corporation Company Profile

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).

Want to see what other hedge funds are holding IRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IRIDEX Corporation (NASDAQ:IRIX).

Institutional Ownership by Quarter for IRIDEX Corporation (NASDAQ:IRIX)

Receive News & Stock Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related stocks with our FREE daily email newsletter.